Publish date:

Everything We Know About BioCryst's New HAE Drug

BioCryst's Hereditary angioedema drug-trial results not compelling.

Hereditary angioedema, or HAE, is a rare genetic blood disorder that causes potentially life-threatening swelling in various body parts. Current treatments used to reduce and prevent swelling are fairly effective, but require injections. BioCryst's (BCRX) - Get BioCryst Pharmaceuticals, Inc. Report once-daily pill BCX7353 could offer a more convenient treatment, but investors await trial results that are more comparable to the inject-able drugs Shire (SHPG) - Get Shire PLC Sponsored ADR Report has in development.

READ THE FULL STORY HERE: BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

This article was written by a staff member of TheStreet.

TheStreet Recommends